Case Study

First Clinical Trial Using Stem Cell Therapy To Treat Septic Shock

Corning HYPERFlask Cell Culture Vessel
Corning HYPERFlask Cell Culture Vessels were used to manufacture single dose treatments for patients with septic shock.

Research using the production of mesenchymal stem cells (MSCs) is expanding—leading to clinically relevant discoveries across therapeutic areas. Led by Dr. David Courtman, Director Biotherapeutics, the Ottawa Hospital Research Institute’s Cell Manufacturing Facility successfully conducted a Phase I clinical trial examining the safety and efficacy of allogeneic bone marrow-derived MSCs as a treatment for patients experiencing septic shock.

In their Phase I trial, freshly cultured allogeneic bone marrow-derived MSCs were dosed into patients with septic shock.1 A single dose was manufactured using the Corning® HYPERFlask® on an as-needed basis. Since dosing was developed on an emergent per-patient basis, researchers were notified of a patient enrollment and had to deliver the dose within 6 hours.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: